[Source](https://github.com/mm80843/T3.5/blob/main/docs/index.md) -- [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) 

# Benef: __Tailored protection for symptomatic and asymptomatic patients__ (PBN__Benef_1189)

## Property: has_BenefDetails

Evaluating differences in efficacy based on symptoms allows for tailored protection strategies, ensuring appropriate measures are taken for each group

## Property: has_Beneficiary

* [reinfected patients with and without symptoms](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_464.md)

## Property: has_BenefReturn

* [Private investors can invest in research to develop targeted protection measures, potentially leading to the development of new therapeutics or improved vaccine strategies.](https://github.com/mm80843/T3.5/blob/main/docs/BenefReturn/PBN__BenefReturn_1325.md)

## Property: has_BenefSource

* [pilz_contributions_2022](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_245.md)

